Antares Pharma (ATRS) Downgraded to Sell at BidaskClub

Antares Pharma (NASDAQ:ATRS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday, March 30th, BidAskClub reports.

Several other equities research analysts have also recently issued reports on the stock. TheStreet upgraded shares of Antares Pharma from a “d” rating to a “c” rating in a research report on Friday, March 1st. Raymond James boosted their price target on shares of Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a research report on Monday, March 4th. Finally, Cowen assumed coverage on shares of Antares Pharma in a research note on Monday, February 25th. They set an “outperform” rating and a $1.99 price objective for the company. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $4.83.

Shares of Antares Pharma stock traded up $0.01 on Friday, hitting $2.72. 649,954 shares of the company traded hands, compared to its average volume of 1,002,186. The stock has a market cap of $436.65 million, a P/E ratio of -68.00 and a beta of 1.11. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.62 and a quick ratio of 2.20. Antares Pharma has a 52 week low of $2.16 and a 52 week high of $3.96.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.06. The firm had revenue of $18.82 million for the quarter, compared to analysts’ expectations of $18.36 million. Antares Pharma had a negative net margin of 10.25% and a negative return on equity of 22.42%. As a group, equities analysts expect that Antares Pharma will post -0.02 EPS for the current year.

In other news, Director Leonard S. Jacob sold 92,078 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $3.00, for a total transaction of $276,234.00. Following the transaction, the director now owns 301,970 shares in the company, valued at approximately $905,910. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jacques Gonella sold 200,000 shares of the stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $3.65, for a total value of $730,000.00. Following the transaction, the director now owns 9,385,848 shares in the company, valued at approximately $34,258,345.20. The disclosure for this sale can be found here. Company insiders own 12.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Antares Pharma by 112.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock valued at $3,162,000 after purchasing an additional 497,523 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Antares Pharma by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after acquiring an additional 84,181 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Antares Pharma by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after acquiring an additional 84,181 shares during the last quarter. J. L. Bainbridge & Co. Inc. acquired a new stake in shares of Antares Pharma in the 3rd quarter worth $101,000. Finally, Allianz Asset Management GmbH increased its stake in shares of Antares Pharma by 17.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 891,286 shares of the specialty pharmaceutical company’s stock worth $2,995,000 after acquiring an additional 132,113 shares during the last quarter. 41.41% of the stock is owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: What is the 52-week high/low?

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.